visnadine
Small moleculeexperimental
Visnadine is a natural vasodilator. It was first isolated from bishop's weed, a plant indigenous to the Mediterranean region which has been used for centuries in Egypt as a spasmolytic. — Wikipedia
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 31, 2020 (NCT03281655)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
CC[C@@H](C)C(=O)O[C@@H]1[C@H](OC(C)=O)c2c(ccc3ccc(=O)oc23)OC1(C)C- Mol. weight
- 388.42 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3989444 ↗
- WikipediaVisnadine ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03281655 | Phase 2 | Mar 31, 2020 | University of Athens, University of Messina, University of Victoria |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Athens | Academic/Hospital | 1 | 0 | 1 | 2020 |
| University of Messina | Academic/Hospital | 1 | 1 | 1 | 2020 |
| University of Victoria | Academic/Hospital | 1 | 0 | 1 | 2020 |
3 organizations
Page 1 / 1